Updated:
Yisheng Capital
Yisheng Capital is the corporate venture arm of I-Life Medical, a Suzhou, China-based company. It provides medical device research, development, and production...
Yisheng Capital
Yisheng Capital is the corporate venture arm of I-Life Medical, a Suzhou, China-based company. It provides medical device research, development, and production services for the global industry. Yisheng Capital has made one investment, in IMSpc Life, a Seed VC investment made on May 28, 2024.
General information
Firm type
Private Equity
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Frequently asked questions
Who runs investment decisions at Yisheng Capital?
The names of Yisheng Capital's principals, investment committee members, and portfolio managers are not publicly disclosed in regulatory filings or press records as of 2026. The firm has maintained an opaque public profile, which is not uncommon among smaller Shanghai-based private equity managers that raised capital primarily from domestic limited partners before China's regulatory tightening.
What investment stages does Yisheng Capital target?
Disclosed strategy documentation indicates Yisheng covers a broad spectrum: seed, start-up, growth equity, and PIPE transactions. This means the firm can deploy into pre-revenue venture rounds, later-stage private companies scaling operations, and publicly listed companies via private placements. Such a wide mandate is efficient for capital deployment but demands deep origination teams across sectors.
Does Yisheng participate in fund commitments or only direct deals?
There is no public record of Yisheng Capital operating a fund-of-funds line or making commitments into third-party-managed vehicles. The disclosed strategy focuses on direct investments—both private and public—which is the dominant model for Chinese private equity firms of its apparent size and vintage.
Which sectors does Yisheng Capital explicitly avoid?
Sector exclusions are not publicly stated. Like many Shanghai generalists, Yisheng likely avoids sectors subject to heightened regulatory scrutiny—such as for-profit education technology and certain aspects of consumer internet—following China's 2021 regulatory reset, but this cannot be confirmed from primary sources.
How does Yisheng Capital source deal flow?
Sourcing channels are not documented in the public domain. Typically, Shanghai-based generalists of this profile rely on domestic advisor networks, government-guided fund relationships, and relationships with local entrepreneurs. Without disclosed portfolio names, the quality and proprietary nature of Yisheng's origination remain unassessable.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: